SCHEMBL3835199

SCHEMBL3835199

CN(C)c1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.44
ALDH1A1 P00352 3/20 0.44
GAA P10253 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ACHE P22303 1/20 0.43
CHEK1 O14757 1/20 0.43
NEK2 P51955 1/20 0.43
LIMK1 P53667 1/20 0.43
DYRK1A Q13627 1/20 0.43
CLK4 Q9HAZ1 1/20 0.43
TAAR1 Q96RJ0 2/20 0.41
KCNN4 O15554 1/20 0.40
HTR6 P50406 1/20 0.39
AOC3 Q16853 1/20 0.39
NSD2 O96028 1/20 0.39
EGFR P00533 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29419644 1.00 MAPT (0.44) MAPTALDH1A1GAASMN1; SMN2TP53
SCHEMBL13504583 0.97 MAPT (0.43) MAPTALDH1A1GAASMN1; SMN2TP53
SCHEMBL14403357 0.83 ACHE (0.43) MAPTALDH1A1GAASMN1; SMN2TP53
SCHEMBL17508132 0.81 ACHE (0.42) MAPTALDH1A1GAASMN1; SMN2TP53
SCHEMBL31469262 0.79 AOC3 (0.45) ALDH1A1GAASMN1; SMN2KDM4EACHE
SCHEMBL27930560 0.79 ACHE (0.40) MAPTALDH1A1GAASMN1; SMN2TP53
SCHEMBL4660214 0.79 AOC3 (0.45) ALDH1A1GAASMN1; SMN2KDM4EACHE
SCHEMBL7690206 0.79 MAPT (0.46) MAPTALDH1A1GAASMN1; SMN2TP53
SCHEMBL17425301 0.79 ACHE (0.40) MAPTALDH1A1GAASMN1; SMN2TP53
SCHEMBL65263 0.78 MAPT (0.55) MAPTALDH1A1GAASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4585895-A Processes for the preparation of mixed squaraine compositions XEROX CORPORATION (US) 1986-04-29 US claimed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
CN-117964493-A Synthesis method of N-methyl o-fluoroaniline 湖南速博生物技术有限公司 2024-05-03 CN disclosed
CN-117482074-A Anti-inflammatory composition comprising N-benzyl-N-methyl-dec-1-amine or derivative thereof as active ingredient 釜山大学校产学协力团 2024-02-02 CN disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
WO-2023106377-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND 旭化成株式会社 2023-06-15 WO disclosed
CN-111662185-B Synthesis method of N-methyl o-fluoroaniline 江苏富鼎化学有限公司 2023-05-05 CN disclosed
CN-112851518-B Synthesis method of N-methyl o-fluoroaniline 江苏中旗科技股份有限公司 2023-02-14 CN disclosed
US-20220223790-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2022-07-14 US disclosed
WO-2021214315-A1 PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) 2021-10-28 WO disclosed
US-4746756-A Photoconductive imaging members with novel fluorinated squaraine compounds XEROX CORPORATION (US) 1988-05-24 US disclosed
US-4621038-A Photoconductive imaging members with novel symmetrical fluorinated squaraine compounds XEROX CORPORATION (US) 1986-11-04 US disclosed
US-4606986-A Electrophotographic elements containing unsymmetrical squaraines XEROX CORPORATION (US) 1986-08-19 US disclosed
US-4585895-A Processes for the preparation of mixed squaraine compositions XEROX CORPORATION (US) 1986-04-29 US disclosed
EP-0146301-A1 Process for synthesizing squaraine compositions XEROX CORPORATION (US) 1985-06-26 EP disclosed
EP-0144206-A2 Process for synthesising squaraine compositions XEROX CORPORATION (US) 1985-06-12 EP disclosed
US-4523035-A BLUE AND GREEN PIGMENTS XEROX CORPORATION (US) 1985-06-11 US disclosed
US-4521621-A Novel squarine systems XEROX CORPORATION (US) 1985-06-04 US disclosed
US-4500715-A CHEMICAL INTERMEDIATES FOR PLANT SAFENING AGENTS AND DYES BAYER AKTIENGESELLSCHAFT (DE) 1985-02-19 US disclosed
US-4268438-A Cationic 1,3,4-thiadiazole dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1981-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 MAPT 1369/4885ALDH1A1 4344/4885GAA 2982/4885
US-20220223790-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND POLYCYCLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE SLCO2A1, SLCO4C1, TMEM109 MAPT 2214/4885ALDH1A1 148/4885GAA 2182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.